Kemin Wu Selected Research

Member 1 Group A Nuclear Receptor Subfamily 6

8/2022

Linear ubiquitination modification of NR6A1 by LUBAC inhibits RIPK3 kinase activity and attenuates apoptosis of vascular smooth muscle cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kemin Wu Research Topics

Disease

3	Pancreatic Neoplasms (Pancreatic Cancer) 11/2014 - 12/2012
2	Abdominal Aortic Aneurysm 01/2022 - 11/2021
2	Neoplasms (Cancer) 11/2014 - 05/2012
1	Atherosclerosis 08/2022
1	Diabetes Mellitus 01/2022
1	Peripheral Arterial Disease 01/2022
1	Hematoma 05/2021
1	Carcinogenesis 11/2014
1	Pain (Aches) 04/2014
1	Neoplasm Metastasis (Metastasis) 12/2012
1	Hepatocellular Carcinoma (Hepatoma) 05/2012

Drug/Important Bio-Agent (IBA)

2	MicroRNAs (MicroRNA)IBA 11/2014 - 05/2012
1	ApolipoproteinsIBA 08/2022
1	CholesterolIBA 08/2022
1	Member 1 Group A Nuclear Receptor Subfamily 6IBA 08/2022
1	Triglycerides (Triacylglycerol)IBA 08/2022
1	LipidsIBA 08/2022
1	CaspasesIBA 08/2022
1	CollagenIBA 08/2022
1	fibrin fragment D (D-dimer)IBA 01/2022
1	BilirubinIBA 01/2022
1	Fibrinogen (Factor I)FDA Link 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Long Noncoding RNAIBA 11/2021
1	Histone Deacetylases (Histone Deacetylase)IBA 04/2014
1	Sirtuin 1IBA 04/2014
1	CytokinesIBA 10/2013

Therapy/Procedure

2	Therapeutics 11/2014 - 12/2012
1	Operative Time 05/2021